CD5L:p40, a novel heterodimeric regulator of type 2 inflammation

J Immunol. 2026 Mar 17;215(3):vkaf348. doi: 10.1093/jimmun/vkaf348.ABSTRACTIL-12p40 heterodimerizes with IL-12p19 and IL-12p35 to produce IL-23 and IL-12, respectively. The functions of IL-12 and IL-23 are best described in T cells in which IL-12 is a potent inducer of Th1 differentiation, whereas I

C Chao Wang

The significance of component-resolved diagnostics in atopic dermatitis

Front Immunol. 2026 Mar 2;17:1711854. doi: 10.3389/fimmu.2026.1711854. eCollection 2026.ABSTRACTAtopic dermatitis (AD) is a common and chronic inflammatory skin disease characterized by an abnormal skin barrier, resulting in skin dryness, pruritus, and an increased risk of allergies and secondary in

M Małgorzata Błażowska

Neuritis nervi optici (NNO)

Klin Monbl Augenheilkd. 2026 Mar 17. doi: 10.1055/a-2685-3349. Online ahead of print.ABSTRACTThe term optic neuritis describes an inflammation of the optic nerve. It encompasses a group of different diseases that vary in their prevalence, clinical course, treatment, and visual prognosis. These inclu

H Heimo Steffen

Long-term comorbidity patterns in juvenile idiopathic arthritis

Clin Exp Rheumatol. 2026 Mar 12. doi: 10.55563/clinexprheumatol/t7zeld. Online ahead of print.ABSTRACTOBJECTIVES: Juvenile idiopathic arthritis (JIA) leads to significant long-term morbidity from articular and extra-articular complications, yet the burden of comorbidities in adults with long-standin

C Carolina Zinterl

Optineurin calibrates STING-mediated type I interferon response

FEBS J. 2026 Mar 17. doi: 10.1111/febs.70490. Online ahead of print.ABSTRACTCyclic GMP-AMP synthase (cGAS) senses cytosolic self and microbial DNA to produce cyclic guanosine monophosphate-adenosine monophosphate (cGAMP), a secondary messenger that activates the endoplasmic reticulum-resident transm

S Sreeram Kaveti

Immune checkpoint inhibitor-induced joint involvement

Presse Med. 2026 Mar 14:104340. doi: 10.1016/j.lpm.2026.104340. Online ahead of print.ABSTRACTEven though immune checkpoint inhibitors (ICI) remain effective treatments for an increasing number of cancers, they are also liable to cause immune-related adverse events (irAE). Rheumatologic manifestatio

J Juliette Quelain